EUVIMEDEUVIMED entdecken
Crossref

Validated HPLC‐UV method for quantification of paxalisib, a pan PI3K and mTOR inhibitor in mouse plasma: Application to a pharmacokinetic study in mice

Ashok Zakkula, Harsha K Tripathy, Rama Murthi Bestha, A B Vinod, Vinay Kiran, Sreekanth Dittakavi iD, Ramesh Mullangi iD

Biomedical Chromatography · 2023-04 · 37 (4)

DOI: 10.1002/bmc.5587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 30.01.2023. Verfasst von Ashok Zakkula und 6 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shamirpet, Hyderabad, India. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paxalisib is a pan‐PI3K and mTOR inhibitor, currently entering into Phase II clinical trials as a potential drug to treat glioblastoma patients. We report the development and validation of a high‐performance liquid chromatography (HPLC) method for the quantitation of paxalisib in mouse plasma as per the US Food and Drug Administration regulatory guidelines. From the mouse plasma, paxalisib and the internal standard (IS; filgotinib) were extracted using ethyl acetate as an extraction solvent. The chromatographic separation of paxalisib and the IS was accomplished on a Symmetry C 18 (250 × 4.6 mm, 5.0 μm) column maintained at 40°C using 10 m m ammonium formate and acetonitrile in gradient conditions at a 0.8 ml/min flow‐rate. The injection volume was 20 μl. The elution was monitored using a photo‐diode array detector set at λ max 280 nm. Paxalisib and the IS eluted at 6.5 and 5.9 min, respectively with a total run time of 10 min. The calibration curve was linear over the range of 111–4,989 ng/ml. Inter‐ and intraday precision and accuracy, stability studies, dilution integrity and incurred sample reanalysis were investigated and the results met the acceptance criteria. The validated HPLC method was extended to assess the pharmacokinetic parameters of paxalisib in mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylinositol 3-KinasesProtein Kinase InhibitorsMiceAnimalsChromatography, High Pressure LiquidReproducibility of ResultsMTOR InhibitorsTOR Serine-Threonine Kinases

Stichwörter der Autor:innen

HPLCmethod validationmouse plasmapaxalisibpharmacokinetics

Substanzen

Phosphatidylinositol 3-KinasesProtein Kinase InhibitorsMTOR InhibitorsTOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • Drug Metabolism and Pharmacokinetics, Laxai Life Sciences Pvt. Ltd, Shamirpet, Hyderabad, India.
  • Karnataka College of Pharmacy, Thirumenahalli, Bangalore, India.

ORCID-Profile: Sreekanth Dittakavi, Ramesh Mullangi

Zitieren

APA

Zakkula, A., Tripathy, H. K., Bestha, R. M., Vinod, A. B., Kiran, V., Dittakavi, S., & Mullangi, R. (2023). Validated HPLC‐UV method for quantification of paxalisib, a pan PI3K and mTOR inhibitor in mouse plasma: Application to a pharmacokinetic study in mice. Biomedical Chromatography, 37(4). https://doi.org/10.1002/bmc.5587

Vancouver

Zakkula A, Tripathy HK, Bestha RM, Vinod AB, Kiran V, Dittakavi S, et al. Validated HPLC‐UV method for quantification of paxalisib, a pan PI3K and mTOR inhibitor in mouse plasma: Application to a pharmacokinetic study in mice. Biomedical Chromatography. 2023;37(4). doi:10.1002/bmc.5587

BibTeX
@article{Zakkula2023,
  author = {Zakkula, Ashok and Tripathy, Harsha K and Bestha, Rama Murthi and Vinod, A B and Kiran, Vinay and Dittakavi, Sreekanth and Mullangi, Ramesh},
  title = {Validated HPLC‐UV method for quantification of paxalisib, a pan PI3K and mTOR inhibitor in mouse plasma: Application to a pharmacokinetic study in mice},
  journal = {Biomedical Chromatography},
  year = {2023},
  volume = {37},
  number = {4},
  doi = {10.1002/bmc.5587}
}
Kostenlos starten →